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1. Introduction 
The term „vasculitis” encompasses a heterogenous group of multisystemic disorders 
characterized pathologically by inflammation and necrosis of the blood vessel wall [1]. 
The sequelae of vascular inflammation depend on the number, site and size of involved 
blood vessels. In vasculitis a disturbances of the blood vesels wall are focal. The segmental 
lesions lead, most common, to stenosis, occlusion and infarction. The lesions can also 
produce aneurysms, vessel wall rupture and haemorrhage. Almost all forms of vasculitis 
can involve the vessels feeding the brain parenchyma and cause stroke-like episodes [2, 
3]. The clinical presentation of involvement the central nervous system (CNS) is very 
variable. Headaches and encephaloppathy are most typical. Meningeal signs, psychiatric 
syndromes, dementia, cranial nerve palsies, epileptic seizures alone or in combination 
with neuropathy/ polyneuropathy or muscle damage , multiorgan involvement and non-
specific systemiec symptoms (fever, weight loss) are also well known symptoms. 
Vasculitis is an infrequent disorder: the overall annual incidence  (excluding giant cell 
arteritis) is estimated to be 31-47 cases/milion, but exist very rare  types of vasculitis such 
as Churg-Strauss where annual incidence amounts ony 1-5 cases/milion [1, 4]. For 
polyarteritis nodosa (PAN) an annual incidence of 1.6 per milion has been described [5]. 
Vasculitis is a rare cause of stroke, even in the young age groups: only 1 case among 515 
consecutive intracerebral haemorrhage, 13 among 1904 consecutive transient ischaemic 
attacs (TIA), 8 out of 254 (3%) stroke patients aged under 50 years [6] and 10 out of 215 
(5%) patients aged under 45 years [7]. Neurological symtoms and stroke may be the first 
manifestation of vasculitis or may complicate the clinical course of previously diagnosed 
case. 
2. Classification of vasculitis 
There have been several proposals for the classification of vasculitis [1, 8-11], but all have 
limitation. The simple division of vasculitis usually consider as primary and secondary [12]. 
According to the Chapel Hill Consensus Conferences (CHCC) the primary systemic 
vasculitides are classified into three main groups: the affecting predominantly large-sized 
vessels, medium- and small-sized vessels, respectively (table 1)  [13]. 
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Vessel size Granulomatous Nongranulomatous 
Large 
 
 
 
Medium 
 
 
 
Small (with ANCA) 
 
 
Small (with immune 
complexes) 
Giant cell arteritis 
Cranial arteritis 
Takayasu arteritis 
 
 
 
 
 
Wegener granulomatosis 
Churg-Strauss syndrome 
 
 
 
 
Polyarteritis nodosa 
Kawasaki disease 
Microscopic polyarteritis 
 
 
 
 
Cryoglobulinemic vasculitis 
Behcet syndrome 
Table 1. Classification of primary vasculitides (according Berlit) 
 
Blood  examinations: 
 Erytrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood cell  differentiation , 
liver enzymes, creatinine, glomerulal filtration rate, coagulation tests with search for 
coagulopaties [especially anticardiolipin-antibodies (ACA), lupus anticoagulant (LA)], 
electrophoresis, creatinine kinase, lactate dehydrogenase (LDH), haptoglobulin, ferritine, 
angiotensin converting enzyme, immunofixation, quantitative evaluation of 
immunoglobulins, search for cryoglobulins, TSH, thyroid antibodies, rheuma factor, 
antinuclear antibodies (ANA),  ds-DNA antibodies, histon antibodies, complement, anti-
Ro (SS-A), anti –La (SS-B) antibodies, 
 c- and p ANCA/MPO [myeloperoxidase [MPO]], anti-endothelial antibodies, drug 
screening, blood culture 
Serologic tests for syphilis, borreliosis, hepatitis B and C, HIV 
 
Urine examination including electrophoresis 
 
Cerebrospinal fluid (CSF): cell  differentiation, isoelectric focussing, cultures, antigens, 
PCR [viruses, bacteria, mycosis] 
Table 2. Laboratory tests which are performed in suspected vasculitis (according Berlit) 
3. Diagnosis 
If the diagnosis of vasculitis is suspected, a comprehensive medical history and physical 
examination should be very carefully carry out. Then appropriate laboratory tests and other 
ancillary procedures must be performed to asses organ damage [12, 14]. Laboratory findings 
suggestive of a systemic vasculitis include an acute inflammatory response like: raised 
erythrocyte sedimentation rate (ESR) and increased values of C-reactive protein (CRP). 
Anemia, thrombocytosis, elevated liver enzymes and low complement are frequent 
associated findings. Specific antibodies in the blood are evaluated in second order of 
laboratory tests in specialistic laboratories. It ought to exclude diseases which can also cause 
the lesions in the blood vesels mimic vasculitis – that’s why should carry out serologic tests 
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for syphilis, borreliosis, hepatitis B and C as well as HIV in such case. In primary angiitis of 
central nervous system (PACNS) serum findings usually are normal, but cerebrospinal fluid 
(CSF) studies reveal inflammatory findings – a mild lymphomonocytic pleocytosis or 
protein elevation. The disorders in CSF are present in more than 90% of patients, but they 
are non specific [15]. Table 2 contains laboratory tests which are carry out in patients with 
suspicion of vasculitis.  
Imaging radiological techniques which demonstrate arterial vessels play significant role in 
securing the diagnosis of vasculitis, and also demonstrate the cerebral involvement [12, 14, 
16, 17, 18]. Computed tomography (CT) and magnetic resonance imaging (MRI) detect 
multiple CNS vascular lesions when only one is clinically apparent. MRI is more sensitive 
than CT and good detect the lesions in the cerebral trunk which is not visible in CT. Multiple 
infarcts in different vascular territories and of different ages are suggestive of vasculitis [17] 
Normal MRI  rather excludes intracranial vasculitis. On digital subtraction cerebral 
angiography (DSA), angio- CT, MR angiography (MRA), areas of stenosis,  dilatation,  
occlusion, microaneurysm, and narrowing in multiple-vessel tributaries, collateral flow, and 
regionally prolonged circulation time are suggestive of vasculitis [16, 17, 18, 19]. MRA offers 
the possibility of directly evaluating small vessel vasculitis. Small vessel vasculitis is 
currently best demonstrated by changes seen in brain parenchyma on MRI, but high field 
strength (7T) [16, 17]. These findings are, however, non specific, as they can be seen in other 
conditions such as vasospasm related to subarachnoid haemorrhage, drugs or severe 
hypertension, diabetes with intracranial atheroma, embolus recanalization, radiation, 
infectious or carcinomatous leptomeningitis, sickle-cell disease, reversible angiopathies, 
dissection. Therefore it is very important to analyse the radiological findings in clinical 
context. MRI performed with and without contrast medium is the good investigation not 
only for detection but also for monitoring cerebral involvements [20]. Noteworthy is 18-
fluorodeoxyglucose positron emission tomography as well as certain MRI techniques which 
allow the visualization of vessel wall inflammation when the lumen is still unaffected on 
angiography, but these are methods high specialistics and not commonly used [16, 17, 21].  
Confirmatory evidence can be obtained from tissue biopsy of occupied organ but this is 
invasive method not always perform. Moreover the lesion in vasculitis is segmental, and it 
can not encounter on involvement vessel [12, 14]. Thut’s why a normal tissue biopsy does 
not exclude vasculitis.  
4. Treatment of vasculitis 
There are few controlled studies on the treatment of vasculitis. Usually a combination of 
steroids and cytotoxic drugs is used, but there is considerable variation between centres on 
current therapeutic regimens [12]. Cytotoxics drugs are usually used if the response to 
steroids is poor, if there are too much steroid side effects, in diseases that respond better to 
cytotoxic agents and in severe cases [12, 18, 22]. 
We present pathological and clinical aspects of most importants primary vasculitides. 
5. Primary vasculitis 
5.1 Primary, large vessel vasculitis 
Giant cell (temporal) arteritis (GCA) 
GCA (Horton disease) is the most common of all the vasculitides. It is a chronic, 
granulomatous vasculitis of large- and medium sized arteries. Women are affected more 
www.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
352 
frequently than men (3:1 to 5:1). Mean age at the beginning of the disorder is 65 years or 
more. The American College of Rheumatology (ACR) diagnostic criteria [23] include at least 
three of: 1. Age 50 years or more, 2. New developed headache, 3. Tenderness of the 
superficial temporal artery, 4. Elevated sedimentation rate, at least 55 mm/h, 5. Giant cell 
arteritis in a biopsy specimen from the temporal artery. The definitive diagnosis of GCA 
requires the pathologic demonstration of biopsy with the typical mononuclear, 
granulomatosus cell infiltration of all mural layers, usually with multinucleated giant cells 
(fig.1). The lesion of vessels involves most often   superficial temporal artery, vertebral, 
ophthalmic and posterior ciliary arteries, seldom external and internal carotid arteries, while 
intracranial arteries are almost never involved [24]. The biopsy is the cornerstone of 
diagnosis and often remains positive for two to six weeks after the commencement of 
treatment but the best delivery is performance of biopsy as quick as possible but this 
procedure can not delay treatment. Besides biopsy may be negative in some patients with 
GCA, due to the presence of skip lesions or to sub-optimal biopsy. Therefore, patients with 
negative biopsy should be managed as having GCA if there is typical clinical and laboratory 
picture [25] . Duplex ultrasonography can detect the characteristic appearance of a 
hypoecholic “halo”, occlusion and stenosis, but requires a high level of experience and 
training. Positron emission tomography scanning can pick up aortic and large vessel 
disease, and 3-tesla MRI has shown mural enhancement in inflamed temporal and others 
arteries. These new techniques can be useful for diagnosis and monitoring the disease, but 
currently are to expensive, not easy accessible, and not replace the temporal artery biopsy.  
Clinicians should remember that jaw and tongue claudication, visual symptoms, 
constitutional symptoms (fever, weigh loss and tiredness) and acute phase response may go 
unrecognised especially if not accompanied by headache [26]. Abrupt and irreversible loss 
of vision due to anterior ischaemic optic neuritis is the most dramatic complication of GCA. 
Two-thirds of the patients had premonitory visual symptoms like blurring, diplopia or 
amaurosis fugax the week preceding visual loss [27]. Cervical and muscular pain can occur, 
usually in the early phase of the disease. Transient ischemic attack (TIA) and stroke are rare 
(about 7%) and often in the vertebrobasilar territory [28]. Very rare stroke is the first 
symptoms of GCA [29]. 
Steroids are the first line drugs in treatment of GCA. High-dose glucocorticosteroid should 
be initiated immediately when clinical suspicion of GCA is raised. In uncomplicated GCA 
prednisolone 40-60 mg (not less than 0.75 mg/kg) daily until resolution of symptoms and 
laboratory (most important decrease of ESR) abnormalities is recomended. In visual loss or 
history of amaurosis fugax as well as in stroke intravenous methylprednisolone 500mg to 1 
g daily for three days before oral prednisolone should be given [25]. During steroids 
treatment it should to remember of bone and gastrointestinal  protection applicating weekly 
bisphosphonate and calcium/vitamin D supplementation, and protein pump inhibitors (eg 
omeprazole, lanzoprazole). Prednisolone is continued in full dose during four weeks or 
until withdrawal of symptoms and lab abnormalities. Then dose is reduced by 10 mg every 
two weeks to 20 mg, then 2.5 mg every two to four weeks to 10 mg, and in the end by 1 mg 
every one to two months, provided there is no relapse. Sometimes the dose reduction is 
more rapid. In case relapsing disease it ought to use steroids again [25].  
Primary angiitis of the CNS (PACNS) 
PACNS is a rare form of vasculitis of unknown cause, which accounts for just 1% of the 
systemic vasculitides [30]. The mean age of onset is 50 years, and men are affected twice as  
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Fig. 1. GCA – biopsy of the wall of the superficial temporal artery (typical multinuclear large 
cell) (from collection of prof. J. Bogousslavsky) 
often as women. It causes focal and diffuse neurological symptoms. Headache and 
encephalopathy are the most frequent initial symptoms. Stroke or focal symptoms develop 
in less than 20% of patients at the onset of the disease [30]. Serologic markers of 
inflammation are typically normal. Seizures have been reported in less than 25% of patients, 
fevers, weight loss, and night sweats have been reported in less than 20% of patients. 
Similarly, the erythrocyte sedimentation rate is elevated in less than 25% od patients. 
Substantial number of patients suspected of having PACNS will have signs and symptoms 
caused by vasospasm rather than true vasculitis of intracerebral vessels. Sometimes in 
difficult to distinguish these two disorders. PACNS typically affects middle-aged men, 
reversible vasoconstriction syndrome is primarily seen in women aged 20 to 40 years. 
Puerperous period, migraines, illicit drug use, and use of over-the counter cold medicines, is 
frequently conncted with vasoconstriction syndrome. Sometimes PACNS mimic cerebral 
tumors [31] 
MRI  should be the neuroimaging modality of choice for patients with suspected PACNS, 
and abnormality are present in 90% to 100% of patients. MRI may demonstrate ischemic and 
hemorrhagic lesions most common seen in the subcortical white matter, followed by the 
deep gray matter, the deep white matter, and the cereberal cortex. Infarcts may be seen in 
approximately 50% of cases; when present , infarcts are usually seen bilaterally in multiple- 
 
Fig.1 
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Fig. 2. CT and agio CT of the brain with lesion on left hemisphere, and typical segmental 
arterial stenosis  in PACNS (owne case) 
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Fig. 3. Brain stereotactic biopsy from lesion in PACNS (lymphocytic cellular infiltrates of 
vessel wall) (own case) 
vessel tributaries, affecting the cortex as well as the subcortex area. Both subarachnoid and 
intraparenchymal haemorrhages occur in approximately 10% of cases. Mass lesions mistaken 
for malignant neoplasms can be seen in as many as 15% of cases. Other common patterns 
include diffuse small-vesel changes of ischemic demyelination. Less common patterns include 
confluent white-matter lesions, which can be mistaken for multiple sclerosis [18, 30, 32]. 
Angiography sometimes demonstrates bilateral vessel stenoses or occlusion consistent with an 
angiitis (fig.2) [12, 18, 30, 32]. In cerebro-spinal fluid some findings have been reported [15, 32]. 
Pleocytosis and a protein elevation are frequent but not specific [15]. 
Criteria for the diagnosis of PANCS were suggested in 1987 by Calabrese and Mallek [33]: 1. 
Acquired neurological deficit unexplained after complete evaluation, 2. Diagnostic cerebral 
angiogram with narrowing of vessels, areas of dilation and/or beaded vessel appearance, 
displacement of vessels or vessel occlusions, 3. No evidence of systemic vasculitis or any 
other condition that could mimic the angiogram findings. 
Definite diagnosis can give brain/leptomeningeal biopsy, which has a 53% sensitivity,  and 
not rare it is negative [12, 30, 32, 34, 35]. Besides that brain biopsy remains the gold standard 
for the diagnosis of PACNS and stereotactic biopsy is generally only recommended for mass 
lesion. The brain biopsy is proposed all patients with a suspected diagnosis of PACNS  
before starting the plan of prolonged immunosuppressant treatment [30], but not always 
patients decide for this invasive procedure. The histological findings of PACNS consist of 
granulomatous inflammation, fibrinoid necrosis of vessel wall or exclusively lymphocytic 
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cellular infiltrates (fig.3.). There was no correlation between the histological pattern and 
clinical manifestations or prognosis [18, 36].  
No controlled therapy studies for CNS angiitis have been performed yet. In general,  a 
combination of steroids and pulse cyclophosphamid (CYC) is recommended [18]. Birnbau 
propose treat patients with definite PACNS initially with oral CYC 2mg/kg/d and 
corticosteroid (usually in the form of prednisone 1mg/kg/d. if the patients has immediate 
life-threatening disease, it begin therapy with methyprednisolone 1g intravenously daily for 
3 days. Thereafter, the patient is given oral prednisone 1mg/kg/d for 1 month, and the dose 
then is tapered slowly over 12 months [30]. During such high doses of prednisone, all 
patients should be received bisphosphonate, calcium and vitamin D, as well as 
pantoprazole, and supplementation of kalium periodically. Appropriate adjustments for 
CYC therapy, considering the patient’s age, renal status, and other comorbidities, have been 
described elsewhere. In addition, all patients should be given Pneumocystis infection 
prophylaxix (eg trimethoprim and sulfamethoxazole 80mg/40mg, 1 tablet daily). Because 
the myelosuppresive effects of CYC are unpredictable it should be complete blood cell 
counts at least every 15 days imaging [30]. The therapy with CYC is management until 
induction of remission. After that is stoped and is continued by others immunosupresants 
like azathioprine or methotrexate. These agents are continued for 2 to 3 years [30]. The 
prognosis of PACNS is uncertain and careful; most patients dying within 1 year. Altered 
consciousness or mental state and diffuse cerebral dysfunction are associated with poor 
outcome, while focal symptoms are associated with better outcome [12, 18, 30, 37].  
In this disease it should remember that a substantial number of patients suspected of having 
PACNS will have signs and symptoms caused by vasospasm rather than true vasculitis of 
intracerebral vessels. The vasoconstriction syndrome is reversible is primarly seen in 
women aged 20 to 40 years. A history of syndromes or provocative agents associated with 
vasospasm, including the puerperium period, migraines, illicit drug use, and use of over-the 
counter cold medicines, is frequently elicited. The most common presenting syndrome is of 
a thunderclap headache of sudden onset and sufficient severity to warrant diagnostic 
evaluation for subarachnoid hemorrhage. Focal symptoms can predominate with stroke or 
TIA as a presenting feature. Cerebrospinal fluid is normal. Prednisone with calcium channel 
blockers are used for treatment reversible vasoconstriction syndrome [30]. The prognosis in 
this disturbance is good. 
Takayasu’s arteritis 
Takayasu’s arteritis is a variant of giant cell arteritis affecting the aorta and its main 
branches to the limbs and the head. This disease is much more common in Asians than in 
Europeans and predominates in young female subjects. ACR diagnostic criteria  include at 
least three of the following: 1. age at disease onset < 50 years, 2. Claudication of extremities 
especially upper limbs, 3. Decrease brachial artery pulse, 4. Blood pressure (systolic) 
difference > 10 mmHg between arms, 5. Bruit over subclavian arteries or abdominal aorta, 6. 
Arteriographic narrowing or occlusion of the aorta, its primary branches or large arteries 
(not due to arteriosclerosis, fibromuscular dysplasia or similar causes [38]. The disease starts 
with nonspecific systemic signs and symptoms such arthralgia, fever, fatigue, headaches, 
rashes and weight loss. In Takayasu’s arteritis there are no specific laboratory abnormalities. 
An elevation of ESR or CRP and a mild anaemia are possible, but the acute phase response 
may be normal. Anti-endothelial antibodies (AEA) can bee present [18]. Main neurological 
symptoms are syncope and visual troubles. TIA or stroke are rare, and they are more often 
secondary to hypertension related to involvement of the renal arteries.  
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Digital subtraction angiography (DSA) is the gold standard for the demonstration of vessel 
stenoses or occlusion. MRI, and MRA, CT angiography, PET and high-resolution ultrasound 
are used more frequently for the investigation of Takayasu’s arteritis [39]. 
Steroids are useful in therapy of the disease, and fifty percent of patients respond to them 
alone in early phase of the illness. The prognosis is relatively benign, 90% of patients being 
alive at 10 years [12]. In 20% of the patients the disease is monophasic and selflimited. Some 
patients need steroids plus CYC or low – dose methotrexate or azathioprine. Angiotensin II 
receptor antagonists are applied for treatment renovascular hypertension. Concomitant 
therapies include low-dose aspirin and statin even in normolipidemic patients [18]. 
Angioplasty and other vascular surgical procedures are used if it’s necessary besides 
pharmacological treatment [40]. 
6. Primary, medium-sized vessel vasculitis 
Periarteritis nodosa (PAN) 
PAN is the systemic necrotizing vasculitis only of medium sized arteries without the 
involvement of smaller vessels. This disease may be associated with hepatitis virus 
infection. The diagnostic criteria of the ACR for the diagnosis of PAN include at least three 
of: 1. loss of weight > 4 kg, 2. livedo reticularis, 3. testicular pain, 4. myalgias, 5. 
mononeuritis or polyneuritis, 6. blood pressure elevation > 90 mmHg, 7. creatinine > 1,5 
mg/dl, 8. hepatitis B or C virus antibodies, 9. pathologic arteriography (aneurysm, 
occlusion), 10. typical histology finding in biopsy of muscle with necrotizing granulomatous 
inflammation (fig. 4.) [12, 18, 41, 42].  
 
 
Fig. 4. Polyarteritis nodosa (PAN) -  muscle biopsy with typical granulocyte infiltrates of 
small vessel wall with occlusion of vascular lumen (own case) 
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Twenty of patients with PAN had brain involvement in the monograph by Schmidley [15]. 
Ischemic stroke, hemorrhages and a progressive encephalopathy, seizures  may occur. This 
disease is severe thats why it should be treated aggressively with steroids (pulses of 
methylprednisolone in severe forms) and cytotoxic drugs, mainly CYC. In  emergency 
situations plasmapheresis may be tried [18]. Eighty percent of subjects who receive 
appropriate treatment are alive at 5 years [12]. 
Kawasaki disease 
This is a rare medium-sized vessel vasculitis that causes stroke or encephalopathy in 
children. Its manifestations include fever, conjunctival infection, infected or fissured lips, 
infected pharynx or “strawberry tongue, erythema of palms or soles or oedema of hand or 
feet, polymorphous non-vesicular rash and cervical adenopathy. Treatment includes iv 
immunoglobulin and aspirin [12]  
7. Primary small vessel vasculitis 
Wegener’s granulomatosis 
This is rare small vessel (arteries and veins) arteritis frequently associated with 
autoantybodies: cANCA/PR3 and sometimes with MPO-ANCA [18]. Men are affected more 
frequent than women. The ACR criteria for classification of Wegener’s granulomatosis 
include at least two of the following four: 1. necrotizing ulcerating inflammation of nose, 
sinuses, mouth, or pharynx, 2.irregular lung infiltrates, 3. nephritis, 4. granulomatous 
vascular and perivascular inflammation. In Wegener’s granulomatosis a nonseptic 
meningitis with enhancement of the basal meninges and the development of an occlusive or 
communicating hydrocephalus are possible. Poyneuropathies, myelopathies and 
cerebrovascular symptoms frequently occur but stroke is a very rare complication [43, 44]. 
Nishino et al. and Fauci et al. descreibed neurologic invpolvement in Wegener’s 
granulomatosis in 22 – 33.6% of patients [45, 46]. Prednisone or CYC are used  for treatment 
45, 46, 47]. During CYC treatment don’t ought exceed a cumulative dose > 30g, and higher 
doses should be strictly avoided [47]. During CYC therapy are useful: antiemetics, bladder 
protection with NaCl infusions and uromitexane perfusor as well as ovarien protection. 
Alternative  treatment option is methotrexate 20-25 mg per week [48] or rituximab [49]. 
Azathioprine can be effective in supporting therapy. The presence of ANCA at diagnosis, 
cardiac or renal involvement increase the risk of relapses.  
Behcet’s disease  
This rare disease is chronic-relapsing vasculitis affecting predominantly the venous system. 
It is more prevalent in the Middle East, Far East and the Mediterranean. Diagnostic criteria 
for Behcet’s disease include at least three of the major signs (oral ulcers, genital ulcers, 
ocular lesions, mainly uveitis, cutaneous involvement-erythema nodosum) or the 
combination of two major signs and one minor (gastrointestinal or central nervous system 
(CNS) or peripherial nervous system (PNS) involvement, arterial lesions,thrombophlebitis, 
arthritis and familiar history) [50]. The course of Behcet’s disease is fluctuating. The 
diagnosis of Behcet’s disease is entirely based on clinical grounds since no pathognomonic 
laboratory or histologic findings exist. CNS involvement occurs in about 30% of patients 
after an average of 5 years. The most common clinical syndromes are encephalitis, 
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meningoencephalitis, and neuropathy as well as headaches, and brainstem symptoms. 
Cerebral oedema and cerebral stroke can also be present. Cerebral oedema is occurred in 
cerebral sinus thrombosis [18]. For the treatment of sinus thrombosis corticosteroids in 
combination with oral anticoagulation are recommended. Pulses of methylprednisolone of 
1000mg (3 -5 days) followed by oral prenisolone (2 – 3 month) are used [51]. Occasionally 
may be used other immunosuppressive agents [52].  
Churg –Strauss syndrome 
Churg – Strauss syndrome is the rarest of the small-vessel vasulitides. Patients report in 
interview allergic diathesis and asthma. Pathologic hallmark of the disease are eosinophil-
rich granulomas. p/ANCA/MPO are present in 40% of patients [53]. The criteria for the 
diagnosis of Churg-Strauss syndrome include at least four of: astma, history of allergy, 
eosinophilia (>10%), mono- or polyneuropathy, migratory or transitory pulmonary 
infiltrates and sinusitis [12]. Renal, lung, and central nervous system are involvement. 6-8% 
of patients present central nervous system symtoms Iike ischemic stroke, ischaemic optic 
neuropathy as well as intracerebral haemorrhage can occur in the disease [53, 54]. These 
patients may bee treated with prednisone alone, but sometimes combined therapy with CYC 
is needed. The remission rate is 80-90%. Patient survival varies between 60% and 97% at 5 
years [56]. 
8. Summary 
Vasculitis is a rare, miscellaneous, and potentially treatable cause of stroke. The diagnosis 
contain labourious tests, neuroradiological image (CT, MRI with arteriography option) and 
often requires invasive procedures, including brain-meningeal biopsy. Treatment of 
vasculitis has an empirical basis and most common it is immunosuppressive. Multicentre 
therapeutic trials are ongoing. A lot of organs are damaged in vasculitis. These sickness 
required a great physician acumen and carefulness, as well as cooperation with others 
specialists. Fast reconnaissance of disease and accustoming of proper treatment can bring 
big benefits patient.  
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